Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies and peptide-based vaccines. Their MultiTAA-specific T cell technology targets multiple tumor-associated antigens to combat hematological malignancies and solid tumors.
Company Overview
Marker Therapeutics is pioneering MultiTAA-specific T cell therapies, offering a novel approach to cancer treatment by targeting multiple tumor-associated antigens, positioning them at the forefront of the immuno-oncology revolution with potential for significant clinical impact and market disruption.
Investment Thesis
Investing in Marker Therapeutics presents a compelling opportunity due to its innovative MultiTAA-specific T cell technology, which has the potential to overcome the limitations of existing immunotherapies. The company's diverse pipeline, including autologous, allogeneic, and off-the-shelf T cell therapies, targets a broad range of hematological malignancies and solid tumors. The ongoing Phase 2 clinical trial for TPIV200 in breast and ovarian cancers represents a near-term catalyst. While the company's negative profit margin of -304.5% and gross margin of -164.1% highlight the risks associated with clinical-stage biotech companies, successful clinical trial outcomes and strategic partnerships could drive significant value creation. The current market capitalization of $0.02 billion suggests that the company may be undervalued if its technology proves successful.
Key Highlights
- Market Cap of $0.02B reflects the company's current valuation and potential for growth upon successful clinical trials.
- P/E Ratio of -1.93 indicates that the company is not currently profitable, typical for clinical-stage biotech companies.
- Profit Margin of -304.5% highlights the significant R&D expenses associated with developing novel immunotherapies.
- Gross Margin of -164.1% reflects the cost of goods sold exceeding revenue, common in early-stage biotech companies.
- Beta of 1.41 suggests that the stock is more volatile than the market, indicating higher risk and potential reward.
Competitors
Strengths
- Novel MultiTAA-specific T cell technology platform.
- Diverse pipeline of autologous, allogeneic, and off-the-shelf T cell therapies.
- Ongoing Phase 2 clinical trial for TPIV200.
- Experienced management team.
Weaknesses
- Limited financial resources.
- Negative profit margin and gross margin.
- Dependence on clinical trial outcomes.
- Small number of employees.
Catalysts
- Upcoming: Data readouts from the Phase 2 clinical trial of TPIV200 in breast and ovarian cancers.
- Ongoing: Expansion of clinical trials to include additional cancer types and patient populations.
- Ongoing: Potential strategic partnerships with pharmaceutical companies and research institutions.
- Ongoing: Development and advancement of off-the-shelf MultiTAA-specific T cell therapies.
Risks
- Potential: Clinical trial failures could negatively impact the company's pipeline and valuation.
- Potential: Regulatory hurdles and delays could delay the commercialization of its therapies.
- Ongoing: Competition from other immuno-oncology companies could limit its market share.
- Ongoing: Dependence on raising capital to fund its operations.
- Potential: Adverse events or safety concerns related to its therapies.
Growth Opportunities
- Expansion of Clinical Trials: Marker Therapeutics has the opportunity to expand its clinical trials to include a broader range of cancer types and patient populations. Successful clinical trial outcomes could lead to regulatory approvals and commercialization of its MultiTAA-specific T cell therapies, driving significant revenue growth. The market for cancer immunotherapies is projected to reach $75 billion by 2028, providing a substantial opportunity for Marker Therapeutics to capture market share.
- Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies and research institutions could accelerate the development and commercialization of Marker Therapeutics' pipeline. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its therapies to market. The timeline for securing these partnerships is ongoing, with potential deals expected within the next 1-3 years.
- Advancement of TPIV200: The ongoing Phase 2 clinical trial for TPIV200 in breast and ovarian cancers represents a significant growth opportunity. Positive results from this trial could lead to regulatory approval and commercialization of the vaccine, addressing a significant unmet need in women's health. The market for breast and ovarian cancer treatments is estimated at $20 billion annually, providing a substantial revenue opportunity for Marker Therapeutics.
- Development of Off-the-Shelf Products: The development of off-the-shelf MultiTAA-specific T cell therapies could significantly expand the reach and accessibility of Marker Therapeutics' technology. These products would eliminate the need for patient-specific manufacturing, reducing costs and timelines. The market for off-the-shelf cell therapies is rapidly growing, with potential applications in a wide range of cancers.
- Geographic Expansion: Expanding its operations beyond the United States could provide access to new markets and patient populations. Europe and Asia represent significant growth opportunities for Marker Therapeutics' therapies. The global market for cancer immunotherapies is expected to grow at a CAGR of 15% over the next five years, driven by increasing demand in emerging markets.
Opportunities
- Expansion of clinical trials to new cancer types.
- Strategic partnerships with pharmaceutical companies.
- Advancement of TPIV200 through clinical development.
- Development of off-the-shelf T cell therapies.
Threats
- Competition from other immuno-oncology companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Difficulty in raising capital.
Competitive Advantages
- Proprietary MultiTAA-specific T cell technology platform.
- Strong intellectual property portfolio with patents protecting its therapies.
- Clinical data demonstrating the efficacy of its therapies.
- Experienced management team with expertise in immuno-oncology.
About
Founded in 1999 and headquartered in Houston, Texas, Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing and commercializing innovative T cell-based immunotherapies and peptide-based vaccines. The company's core technology revolves around MultiTAA-specific T cells, which are non-engineered tumor-specific T cells designed to recognize and eliminate cancer cells expressing multiple tumor-associated antigens. This approach aims to overcome the limitations of traditional immunotherapies that target only a single antigen, potentially leading to more durable and effective responses. Marker Therapeutics' pipeline includes autologous T cell therapies for lymphoma and various solid tumors, allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia, and off-the-shelf products for various indications. Additionally, the company is developing TPIV100/110, peptide-based immunotherapeutic vaccines targeting breast and ovarian cancer cells, and TPIV200, currently in Phase 2 clinical trials for breast and ovarian cancers. With a focus on addressing unmet needs in hematological malignancies and solid tumors, Marker Therapeutics is striving to deliver transformative therapies that improve patient outcomes and revolutionize cancer treatment.
What They Do
- Develops MultiTAA-specific T cell therapies for cancer treatment.
- Creates immunotherapies that target multiple tumor-associated antigens.
- Manufactures non-engineered tumor-specific T cells.
- Offers autologous T cell therapies for lymphoma and solid tumors.
- Develops allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia.
- Creates off-the-shelf T cell products for various cancer indications.
- Develops peptide-based immunotherapeutic vaccines for breast and ovarian cancer.
Business Model
- Develops and patents novel T cell-based immunotherapies and peptide-based vaccines.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Seeks regulatory approval from the FDA and other regulatory agencies.
- Commercializes its therapies through direct sales and marketing or through partnerships with pharmaceutical companies.
Industry Context
Marker Therapeutics operates within the rapidly evolving immuno-oncology landscape, a market projected to reach billions of dollars in the coming years. The company's MultiTAA-specific T cell technology positions it as a potential disruptor in the field, offering a novel approach to cancer treatment. Competitors like AEON Biopharma, BOLT Biotherapeutics, CLRBio, COCP, and EVGN are also vying for market share with various immunotherapy approaches. The increasing prevalence of cancer and the growing demand for personalized medicine are driving the growth of the immuno-oncology market, creating significant opportunities for companies like Marker Therapeutics.
Key Customers
- Patients with hematological malignancies, such as lymphoma and leukemia.
- Patients with solid tumors, such as breast and ovarian cancer.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies seeking to license or acquire novel cancer therapies.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1M | -$2M | $-0.12 |
| Q2 2025 | $861,184 | -$4M | $-0.29 |
| Q1 2025 | $349,104 | -$4M | $-0.40 |
| Q4 2024 | $2M | -$4M | $-0.42 |
Source: Company filings
Chart & Info
Price Chart
Marker Therapeutics, Inc. (MRKR) stock price: $1.43 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in Marker Therapeutics' future prospects, indicating that management believes in the company's growth potential.
- •Community sentiment has shifted positively, with discussions around recent advancements in their T cell therapy technology generating excitement.
- •The company has made significant progress in clinical trials, which has bolstered investor optimism about their innovative treatment solutions.
- •Market perception is improving as analysts highlight the potential for Marker Therapeutics to capture a larger share of the immunotherapy market.
Why Bear
- •There are lingering concerns about the pace of regulatory approvals, which could delay the commercialization of their therapies and impact investor confidence.
- •Recent social sentiment reflects skepticism from some investors regarding the long-term viability of their treatment options amidst competition.
- •The company has faced challenges in securing funding, which raises questions about its ability to sustain operations and continue research and development.
- •Market perception remains cautious, with some analysts highlighting the risks associated with the biotech sector's volatility and potential for unforeseen setbacks.
Latest News
-
Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St. · Feb 19, 2026
-
High Growth Tech Stocks In The US Market February 2026
Simply Wall St. · Feb 18, 2026
-
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St. · Feb 16, 2026
-
High Growth Tech Stocks In US With Promising Potential
Simply Wall St. · Feb 10, 2026
Technical Analysis
Rationale
AI-generated technical analysis for MRKR including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Marker Therapeutics, Inc. (MRKR) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for MRKR.
Make a Prediction
Set your price target for Marker Therapeutics, Inc. (MRKR), choose a timeframe, and track your prediction accuracy.
Current price: $1.43
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRKR.
Price Targets
Wall Street price target analysis for MRKR.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 8/100
Revenue grew 99.1% YoY, showing strong top-line momentum well above industry average.
-
Gross Margin 3/100
Gross margin of -164.1% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Limited cash of $19M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 10/100
Investing 204.3% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 2.41% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates MRKR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Exploring 3 High Growth Tech Stocks In The US Market
High Growth Tech Stocks In The US Market February 2026
Exploring 3 High Growth Tech Stocks in the US Market
High Growth Tech Stocks In US With Promising Potential
Frequently Asked Questions
What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumors. Their core technology, MultiTAA-specific T cells, targets multiple tumor-associated antigens to enhance the effectiveness of cancer treatment. The company's pipeline includes autologous, allogeneic, and off-the-shelf T cell therapies, as well as peptide-based vaccines, addressing a broad range of cancer indications. Marker Therapeutics aims to revolutionize cancer treatment by providing more effective and durable therapies for patients.
Is MRKR stock a good buy?
MRKR stock presents a high-risk, high-reward investment opportunity. The company's innovative MultiTAA-specific T cell technology holds significant potential, but it is still in the early stages of clinical development. The negative profit and gross margins reflect the company's current focus on R&D. Successful clinical trial outcomes and strategic partnerships could drive significant value creation. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in MRKR stock. The current market cap of $0.02B suggests potential upside if the technology succeeds.
What are the main risks for MRKR?
The main risks for MRKR include clinical trial failures, regulatory hurdles, competition from other immuno-oncology companies, and the need to raise additional capital. Clinical trial failures could significantly impact the company's pipeline and valuation. Regulatory delays or rejections could delay or prevent the commercialization of its therapies. Competition from larger and more established companies could limit its market share. The company's dependence on raising capital to fund its operations also poses a risk, as it may be difficult to secure funding on favorable terms.
Is MRKR a good stock to buy?
Whether MRKR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the MRKR MoonshotScore?
The MoonshotScore for MRKR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is MRKR data updated?
MRKR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to MRKR is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for MRKR?
Growth catalysts for Marker Therapeutics, Inc. (MRKR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Marker Therapeutics, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are MRKR's main competitors?
Marker Therapeutics, Inc. (MRKR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether MRKR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about MRKR?
Wall Street analyst coverage for MRKR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is MRKR's market cap?
Market capitalization (market cap) for MRKR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows MRKR's current market cap alongside enterprise value and other valuation metrics.
How has MRKR stock performed recently?
MRKR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing MRKR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in MRKR?
Key risk categories for MRKR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures MRKR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling MRKR?
Insider trading activity for MRKR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is MRKR a good stock for beginners?
Marker Therapeutics, Inc. (MRKR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is MRKR for first-time investors?
Every stock carries risk, including Marker Therapeutics, Inc. (MRKR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like MRKR.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial situation.